Drug delivery

Drug delivery concerns how a therapeutic substance is presented to a biological system: where it becomes available, over what time and in what form. Formulation, a carrier material and the route of administration can change the resulting transport. Drug release kinetics describes escape from a formulation or reservoir; pharmacokinetics additionally concerns what happens as the substance moves through and is removed from the body. These are related stages rather than interchangeable measurements.

A motivating historical development was the use of polymers for sustained release of proteins and other macromolecules, reported by Robert S. Langer and Judah Folkman in 1976.^[ref] The engineering question includes whether a carrier can retain a substance initially and then make it available over time while preserving the intended activity.

An elementary reservoir model separates remaining material from cumulative release. If the remaining amount $M(t)$ obeysthen $M(t)=M_0{e}^{-kt}$ and the released fraction is $1-e^{-kt}$. For an illustrative reservoir-release half-time of six hours, $k=\ln 2/(6\mathrm{h})$. Half has been released at six hours and three quarters at twelve hours. The second six-hour interval releases one quarter of the initial amount, even though the first interval released one half. These are model fractions, not a drug regimen; the reservoir-release half-time is not an elimination half-life measured in a person.

An in vitro drug release test can place a formulation in a controlled medium, separate released material from retained material and measure amount against time. The apparatus can influence the answer. The FDA’s technical account explains that passive transport through a dialysis membrane can limit the measured response; its adaptive-perfusion prototype instead uses pressure-driven separation to investigate release from complex formulations.^[ref]

A useful experimental record therefore states the medium, temperature, separation method, sampling schedule and material balance. A slowly changing measured concentration could reflect slow carrier release, slow transport through the apparatus or both. Comparing apparatus conditions and accounting for material remaining in the carrier helps distinguish these mechanisms. Evidence about release under those conditions must then be related to the biological environment before making claims about tissue exposure or therapeutic effect.

An in vitro drug release test measures the amount or rate at which a substance leaves a formulation under specified laboratory conditions. The medium, temperature, agitation or flow, separation method and sampling schedule define the experiment. A measured release curve is therefore a property of a formulation–apparatus system under those conditions, rather than a direct measurement of the concentration in a person.

A typical design places the formulation in contact with a receiving medium, separates released material from the carrier and measures concentration at several times. The primary FDA technical account describes pressure-driven separation as an alternative to passive dialysis-membrane transport for complex formulations. It emphasizes that the separation step can itself limit the observed rate.^[ref]

Repeated sampling requires a material balance. Suppose a well-mixed receiver has constant volume $V$. At each observation a volume $v$ is removed and replaced with blank medium. If $C_j$ is the concentration immediately before the $j$th withdrawal, the cumulative amount transferred into the receiver by time $t_n$ isThe first term is material still in the receiver; the sum is material removed at earlier observations. This sampling correction in drug release testing assumes matched replacement, a well-mixed receiver and no unmeasured loss or chemical transformation.

For illustrative $V=100\mathrm{mL}$, $v=5\mathrm{mL}$, $C_1=0.10\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$ and $C_2=0.18\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$, the amount at the second observation is $18+0.5=18.5\mathrm{mg}$, not just $18\mathrm{mg}$. These chosen values demonstrate accounting; they are not a formulation specification or dosing instruction.

An informative experiment also accounts for material retained in the formulation and material lost to the apparatus. Adsorption, incomplete separation or degradation can change a measured concentration without the same change in carrier release. A control without the carrier and a recovery check address different parts of this problem. Comparing the measured curve under several justified apparatus conditions helps distinguish drug release kinetics from transport and analytical limitations.

Sampling correction in drug release testing is a material-balance adjustment for the substance removed, added or diluted when a receiver is sampled repeatedly. A measured concentration describes material still present at that moment; cumulative release also includes material withdrawn earlier. The distinction belongs to interpretation of an in vitro drug release test, whose transport and separation conditions are part of the measured system.^[ref]

Let $V_n$ and $C_n$ be receiver volume and concentration just before the $n$th withdrawal. At earlier observations $j<n$, remove volume $v_j$ at concentration $C_j$ and add volume $w_j$ containing concentration $b_j$. With initial receiver amount $M_{\mathrm{init}}$, conservation gives the cumulative amount contributed by the formulation:The terms account for material remaining, material already removed and material supplied from elsewhere. The equation assumes that measured species is conserved and that the receiver is well mixed; adsorption or chemical transformation requires additional terms.

For initially blank medium, blank replacement and constant volume $V$, this reduces to $V{C}_n+{\sum }_{j<n}{v}_j{C}_j$. If the aliquots are not replaced, the current volume instead satisfies $V_n=V_0-{\sum }_{j<n}{v}_j$.

Consider an illustrative receiver initially containing $100\mathrm{mL}$. Withdraw $10\mathrm{mL}$ at $C_1=0.20\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$ without replacement. At the next observation, $V_2=90\mathrm{mL}$ and $C_2=0.30\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$, so the cumulative amount is $27+2=29\mathrm{mg}$. Incorrectly retaining the initial volume in the calculation would give $32\mathrm{mg}$. These chosen numbers illustrate accounting, not a formulation specification.

The sampling schedule and replacement protocol must therefore accompany a release curve. A decline in concentration after dilution does not imply that previously released material returned to the carrier. Similarly, a finite-difference drug release rate should be calculated from corrected cumulative amounts, with uncertainty and any shared measurement errors carried through the calculation.

Drug release kinetics describes how the amount leaving a formulation changes with time. Let $M_0$ be the initially releasable amount and $M_{\mathrm{rel}}(t)$ the cumulative amount released. The released fraction and instantaneous drug release rate areA fraction has no units; a rate has units of amount per time. These definitions also require stating the releasable amount used for normalization, rather than silently identifying it with every molecule initially loaded.

Several simple models give distinct curve shapes. Constant-rate release gives $M_{\mathrm{rel}}=r_{0}t$ until the available amount is exhausted. First-order depletion of a reservoir gives $F=1-e^{-kt}$, with an amount released per time that declines as the reservoir empties. In a suitable early-time diffusion-controlled drug release regime, a model may instead give $F=a\sqrt{t}$. Thenso equal increments of released fraction do not occur in equal time intervals. The square-root expression is a limited-time model, not a law that applies from arbitrarily small times through complete release.

For an illustrative curve $F(t)=0.10\sqrt{t/\mathrm{h}}$, the fractions at one, four and nine hours are $0.10$, $0.20$ and $0.30$. The mean fraction released per hour in the intervals $0$–$1$, $1$–$4$ and $4$–$9$ hours is respectively $0.10$, $0.0333$ and $0.020$. A plot with equally spaced vertical increments can therefore conceal a strongly changing release rate.

The mechanism must be tested, not inferred solely from a convenient curve fit. Diffusion, material erosion, changing geometry and the measurement apparatus can produce overlapping features. The historical polymer sustained-release work and the modern FDA assay account illustrate the separate tasks of designing a carrier and measuring what it releases.^[ref][ref] A defensible comparison states the time range, normalization, sampling correction and physical assumptions, then checks whether the proposed mechanism is consistent with additional observations.

Diffusion-controlled drug release occurs when molecular transport down a concentration gradient controls the relevant release time scale. It is a mechanism defined for a particular material, geometry and environment, rather than a name for every slowly changing release curve. A classic theoretical treatment by T. Higuchi distinguishes several matrix and geometrical models.^[ref]

A simple example is an initially uniform dissolved substance of concentration $c_0$ in a planar material, with constant diffusion coefficient $D$. At early times, approximate the material as the half-space $x>0$ and impose a perfect sink condition in drug release, $c(0,t)=0$. Solving the diffusion equation givesFick's first law then gives outward mass flux of magnitudeThis derivation is for dissolved material under the stated boundary condition; it does not identify every square-root law with the same solid-particle matrix model.

For a finite layer of thickness $L$ releasing through one face, the early-time fraction is approximately $F=2\sqrt{Dt/\pi }/L$. With illustrative $L=0.10\mathrm{mm}$ and $D=10^{-12}{\mathrm{m}}^2{\mathrm{s}}^{-1}$, the time scale $L^2/D$ is $10^4\mathrm{s}$, and at $100\mathrm{s}$ the approximation gives $F\approx 0.113$. Extending it to $10^4\mathrm{s}$ would give $F>1$, demonstrating its failure once the finite size matters. The initial mathematical singularity in $J(t)$ likewise reflects idealized initial and boundary conditions.

A useful experimental check changes thickness while keeping material and boundary conditions comparable: this diffusion model predicts a time scale proportional to $L^2$. Swelling, changing diffusivity, degradation or external transport can alter that scaling. A membrane used by the measurement apparatus can also limit transport, so observing a slow curve alone does not locate the controlling resistance inside the formulation.^[ref]

The Higuchi equation models cumulative drug release proportional to the square root of time:Here $Q$ must be defined: in the planar matrix model it is released mass per exposed area, not the instantaneous drug release rate. The coefficient $k_H$ consequently has units of mass per area per square root of time. Takeru Higuchi’s 1963 primary paper distinguishes drug dispersed in a homogeneous matrix from drug leached from a granular matrix and considers planar and spherical geometries.^[ref]

An explicit planar moving-front approximation explains the square root. Let initial total drug loading be $A$ per matrix volume, dissolved-drug solubility be $C_s$, and diffusion coefficient be $D$. Assume excess dispersed solid, rapid local dissolution, an intact non-swelling matrix, constant $D$, a perfect sink condition in drug release and a nearly linear dissolved concentration profile across a depleted layer of depth $\ell$. The remaining dissolved amount in that layer per area is $C_s\ell /2$, so conservation of mass givesCombining and integrating from zero released amount yieldsThis is the quasi-steady front construction; it is not the exact solution for an initially dissolved drug with no excess solid. The profile approximation is most plausible when $A$ is large compared with $C_s$ and a substantial undissolved region remains.

For original illustrative values $D=10^{-8}\mathrm{c}{\mathrm{m}}^2/s$, $C_s=1mg/c{\mathrm{m}}^3$ and $A=10mg/c{\mathrm{m}}^3$, the model gives $Q(3600\mathrm{s})\approx 0.0262mg/c{\mathrm{m}}^2$. At four hours it predicts twice that released amount, not four times. The depleted-layer depth at one hour is approximately $27.5\mu \mathrm{m}$. A finite matrix cannot sustain the law indefinitely: once the front approaches the far boundary, the assumed geometry and drug inventory must be reconsidered.

A useful experiment plots corrected released mass per area against $\sqrt{t}$ and checks whether the apparent slope changes with medium flow or formulation thickness. A straight segment alone does not identify the mechanism. External transport resistance, swelling or changing diffusivity can invalidate the model even if a short data segment looks nearly linear. Sampling correction in drug release testing and a specified exposed area are therefore part of interpreting a fitted $k_H$.

A perfect sink condition in drug release is an idealized receiving boundary that removes released drug fast enough for its concentration there to be treated as zero. In diffusion-controlled drug release, this preserves the largest concentration drop available at the exposed boundary. It is a condition on transport at the release surface, rather than a statement that the entire apparatus contains no drug.

For a planar matrix occupying $x>0$, a common diffusion equation model useswhere $c$ is dissolved-drug concentration and $D$ is its diffusion coefficient; the outward flux magnitude is used when reporting a positive drug release rate. A finite mass-transfer boundary in drug release instead allows a nonzero surface concentration. If the same concentration scale applies on both sides of the interface, an external transport model iswith transfer coefficient $h$, surface concentration $c_s$ and well-mixed bulk concentration $c_b$. A small $c_b$ does not force $c_s$ to be small when a stagnant layer or membrane imposes substantial resistance.

An original finite-reservoir example separates capacity from transport. Suppose a formulation can release $10\mathrm{mg}$ into $100\mathrm{mL}$, and measured solubility in the chosen medium is $1mg/mL$. Even after complete release the well-mixed bulk concentration is only $0.10mg/mL$. In a simple saturated-interface dissolution model $J=h(c_{\mathrm{sat}}-c_b)$, that concentration still reduces flux to $90\%$ of its zero-bulk-concentration value. Large capacity makes a zero-concentration approximation plausible to a chosen tolerance; it does not make the approximation exact.

A useful experimental test compares in vitro drug release test curves while increasing receiving volume or flow, with temperature and medium chemistry controlled. Sampling and medium replacement require sampling correction in drug release testing. If increasing external transport changes the curve, apparatus resistance or accumulation may still matter. The FDA’s primary account of adaptive perfusion describes pressure-driven filtration designed to avoid rate limitation by a passive dialysis membrane.^[ref]

The ideal boundary should be distinguished from a method’s practical sink criterion. The FDA’s 1997 dissolution guidance discusses medium, apparatus and agitation together and explicitly allows justified non-sink tests; a zero boundary is a modelling choice to be checked against the actual experiment.^[ref]

A finite mass-transfer boundary in drug release represents a release surface whose receiving medium removes drug at a finite rate. The surface concentration can therefore exceed the bulk concentration. This is an alternative to imposing a perfect sink condition in drug release directly at the matrix surface.

Write the outward mass flux aswhere $h$ is a transfer coefficient, $c_s$ is surface concentration and $c_b$ is bulk concentration on the same concentration scale. Combined with a diffusion equation inside the matrix, this is a Robin boundary condition: surface value and concentration gradient are coupled. If the two phases use different concentration scales, an appropriate partition relation is also needed rather than silently equating them.

A steady planar example makes the resistances explicit. Suppose a matrix layer of thickness $L$ has a maintained concentration $c_i$ at its inner face and constant diffusion coefficient $D$. ThenThe matrix resistance $L/D$ and external resistance $1/h$ add. This calculation assumes a maintained inner reservoir; it is not a complete transient solution for a depleting dosage form.

The mass-transfer Biot number for drug release compares those resistances:For $D=10^{-12}{\mathrm{m}}^2/s$, $L=10^{-4}\mathrm{m}$ and $h=10^{-7}m/s$, ${\mathrm{Bi}}_m=10$ and the flux is about $90.9\%$ of the negligible-external-resistance value. Doubling $h$ raises this to about $95.2\%$; it does not double the flux because matrix resistance remains.

The distinction is experimentally important. Increasing stirring, flow or membrane permeability tests whether receiving-side transport limits an observed release curve, although other experimental conditions must be controlled. The FDA’s primary adaptive-perfusion description specifically identifies passive dialysis-membrane transport as potentially rate-limiting and describes pressure-driven tangential filtration as an alternative.^[ref] Small bulk concentration alone cannot establish negligible surface resistance.

The mass-transfer Biot number for drug releasecompares internal diffusive resistance with external mass-transfer resistance in a specified release model. Here $h$ is a receiving-side transfer coefficient, $L$ the chosen matrix transport length and $D$ the internal diffusion coefficient. Its value is dimensionless. The definition requires compatible concentration scales; interfacial partitioning must be included if the phases do not share one.

For the steady planar model in finite mass-transfer boundary in drug release,A large ${\mathrm{Bi}}_m$ means external resistance is small relative to the specified internal resistance. A small ${\mathrm{Bi}}_m$ means receiving-side transport can dominate. The comparison says nothing by itself about whether the bulk concentration $c_b$ is near zero, whether $D$ is constant or whether the chosen steady model applies.

The sink-boundary approximation error in drug release can be quantified in this model. With fixed $c_i-c_b$, let $J_{\infty }=D(c_i-c_b)/L$ be the negligible-external-resistance flux. ThenRequiring this last error to be no more than $5\%$ gives ${\mathrm{Bi}}_m\ge 19$. If the error is instead divided by the actual finite-resistance flux $J$, the ratio is $1/{\mathrm{Bi}}_m$ and the corresponding threshold is $20$. A numerical rule is incomplete without its denominator and model assumptions.

For an original example with $D=10^{-12}{\mathrm{m}}^2/s$, $L=100\mu \mathrm{m}$ and $h=2\times 10^{-7}m/s$, ${\mathrm{Bi}}_m=20$. The external-resistance-free approximation exceeds the model flux by $5\%$ relative to $J$, or about $4.76\%$ relative to $J_{\infty }$.

A release experiment can change receiving flow or membrane transport while keeping the formulation fixed. The FDA’s adaptive-perfusion account specifically contrasts passive dialysis-membrane diffusion with pressure-driven separation.^[ref] Such observations motivate checking external resistance; a fitted release curve alone does not measure $h$, $D$ and $L$ independently.

Sink-boundary approximation error in drug release is the difference between a release prediction using an ideal receiving boundary and one that accounts for the actual boundary. The reference prediction and the error denominator must be specified. Finite external resistance and nonzero bulk drug concentration are separate departures from a perfect sink condition in drug release.

For the maintained-reservoir steady planar model, let the internal concentration be $c_i>0$, receiving bulk concentration $c_b$, matrix thickness $L$, internal diffusion coefficient $D$ and external transfer coefficient $h$. With compatible concentration scales,The ideal zero-bulk, negligible-external-resistance prediction is $J_0=D{c}_i/L$. Defining $\beta =c_b/c_i$ and the mass-transfer Biot number for drug release $B=hL/D$ givesThis is the combined boundary-resistance and bulk-concentration error in drug release for the stipulated model. It is not an exact transient error formula for every dosage form.

An original example with $B=20$ and $\beta =0.10$ gives $J/J_0=6/7$. The ideal flux overpredicts by about $14.3\%$ relative to $J_0$, or $16.7\%$ relative to $J$. Making external transport arbitrarily fast still leaves the concentration-related error floor $\beta$ in the first error convention.

The model also supplies a transparent tolerance rule. For $0\le \beta <\epsilon <1$, requiring $(J_0-J)/J_0\le \epsilon$ givesAt $\epsilon =0.05$ and $\beta =0.01$, the threshold is $23.75$. If bulk accumulation already exceeds the tolerance, increasing $h$ alone cannot meet it.

Experimentally, changing receiving volume tests accumulation, while changing flow or membrane transport tests external resistance; sampling correction in drug release testing is needed when material is removed. The FDA’s primary adaptive-perfusion account specifically identifies passive membrane transport as potentially rate-limiting.^[ref] Separating the two effects prevents a large receiving volume from being mistaken for proof of an ideal surface boundary.

This error combines two departures from an ideal sink prediction: resistance between the releasing surface and receiving liquid, and drug already present in that liquid. For the steady planar reservoir model in sink-boundary approximation error in drug release, let $J_0=D{c}_i/L$ be the ideal flux, $B=hL/D$ the mass-transfer Biot number for drug release and $\beta =c_b/c_i$. Assume $D,L,h,c_i>0$ and $0\le \beta \le 1$, with concentrations expressed on compatible scales. ThenWriting the isolated resistance error as $e_R=1/(1+B)$ givesSimply adding $\beta$ and $e_R$ counts their overlap twice. For example, $B=9$ and $\beta =0.04$ give $e=0.136$, rather than $0.14$. This error uses the ideal flux as denominator; the overprediction relative to actual flux is $e/(1-e)\approx 0.1574$.

A useful design calculation solves for how much bulk accumulation is permissible. For a requested tolerance $0<\epsilon <1$,The right side is nonnegative only if $B\ge (1-\epsilon )/\epsilon$. Even zero initial bulk concentration cannot rescue too large an external resistance. At $B=99$ and $\epsilon =0.02$, the permitted bulk fraction is about $0.01010$. For a maintained $c_i=1\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$ and a well-mixed receiving volume $100\mathrm{mL}$, this corresponds to about $1.01\mathrm{mg}$ accumulated in the liquid, assuming no removal or other drug sources. This is an illustrative model calculation, not a general assay acceptance threshold.

Increasing receiving volume primarily limits $\beta$; changing flow or membrane transport can change $B$. The FDA's adaptive-perfusion apparatus specifically replaces potentially rate-limiting passive membrane diffusion with pressure-driven tangential filtration.^[ref] Comparing flow conditions and volumes can distinguish the two limitations. A finite reservoir, changing internal profile, partitioning or sampling requires its own mass balance before this steady expression can be interpreted as an error estimate.

A drug release rate is the amount released from a formulation per unit time. If $M_{\mathrm{rel}}(t)$ is cumulative released amount, the instantaneous rate isIts units are amount per time, such as mass per hour. Dividing by a reference amount gives a fractional rate; dividing by release area gives a mass flux. These normalizations answer different questions and should be stated explicitly.

In discrete measurements, one commonly obtains an interval mean:For illustrative cumulative amounts $0$, $2$ and $3\mathrm{mg}$ at zero, one and three hours, the interval means are $2$ and $0.5\mathrm{mg}{\mathrm{h}}^{-1}$. The second value is an average over two hours, not necessarily the instantaneous rate at their midpoint. A decreasing rate can coexist with a cumulative amount that continues to increase.

Differentiation also amplifies measurement noise. With times treated as exact, propagation of uncertainty givesFor independent amount errors with standard deviation $0.10\mathrm{mg}$ each, a one-hour interval gives rate standard deviation about $0.141\mathrm{mg}{\mathrm{h}}^{-1}$; shortening the interval to $0.10\mathrm{h}$ raises it to about $1.41\mathrm{mg}{\mathrm{h}}^{-1}$. Repeated-sampling corrections can introduce shared errors, so independence must not be assumed automatically.

An in vitro drug release test measures release through an apparatus, and the separation step can influence the rate observed.^[ref] Reporting the amount definition, normalization, time interval, sampling correction in drug release testing and uncertainty makes a rate estimate interpretable. A smoother fitted derivative can be useful, but it also introduces assumptions about the curve between observations.